Basic Information
| LncRNA/CircRNA Name | ANRIL |
| Synonyms | CDKN2B-AS1 |
| Region | GRCh38_9:21994778-22121097 |
| Ensemble | ENSG00000240498 |
| Refseq | NR_003529 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | laryngeal squamous cell cancer |
| ICD-0-3 | C32.3 |
| Methods | RT-qPCR, Western blot, Dual luciferase reporter assay |
| Sample | laryngeal papilloma (LP) tissues,cell lines carrying SV-40T (NP69, BNCC338439), LSCC cell lines (TU177, BNCC341383, AMC-HN-8, BNCC338377) |
| Expression Pattern | up-regulated |
| Function Description | CDKN2B-AS1 was upregulated in LSCC tissues, and the upregulation of CDKN2B-AS1 was correlated with overall survival, advanced clinical stage, and lymph node metastasis. In AMC-HN-8 cells, the knockdown of CDKN2B-AS1 by siRNA inhibited cell viability, blocked cell cycle in G1 phase, and increased the expression levels of cyclin-dependent kinase inhibitor 1A (p21), cleaved caspase3, and cleaved PPoly (ADP-Ribose) polymerase.The upregulation of CDKN2B-AS1 was correlated with overall survival, advanced clinical stage, and lymph node metastasis and promoted LSCC cell growth via miR-324-5p/ROCK1 axis. |
| Pubmed ID | 31960744 |
| Year | 2020 |
| Title | Regulating of Cell Cycle Progression by the lncRNA CDKN2B-AS1/miR-324-5p/ROCK1 Axis in Laryngeal Squamous Cell Cancer |
External Links
| Links for ANRIL | GenBank HGNC NONCODE |
| Links for laryngeal squamous cell cancer | OMIM COSMIC |